Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
HSPG2
REST API REST API
Homo sapiens
HSPG2 is differentially expressed in 277 experiments: 171 organism parts: bone marrow, cerebellum, ... (169 more);, 223 disease states: normal, glioblastoma, ... (221 more);, 96 cell types 427 cell lines 37 compound treatments and 72 other conditions.
Synonyms SJS1, PRCAN, perlecan
Orthologs HSPG2 (Gallus gallus)   Hspg2 (Mus musculus)   F1M566_RAT (Rattus norvegicus)   hspg2 (Danio rerio)   HSPG2 (Bos taurus)   hspg2 (Xenopus laevis)   Q6TYZ5_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term angiogenesis, plasma membrane, protein localization, protein binding, extracellular space, proteinaceous extracellular matrix, extracellular region, basal lamina, cardiac muscle tissue development, basement membrane, cell adhesion, lipid metabolic process, lipoprotein lipase activity, protein C-terminus binding, extracellular matrix organization, extracellular matrix, brain development, calcium ion binding, endochondral ossification, chondrocyte differentiation, embryonic skeletal system morphogenesis, cartilage development involved in endochondral bone morphogenesis, lipoprotein metabolic process
InterPro Term Ig_V-set, SEA, Ig_sub, EGF_laminin, Immunoglobulin, Laminin_B_type_IV, Laminin_G, Ig-like, EGF, Laminin_B_subgr, Ig_sub2, Laminin_G_2, EGF_3, EGF-like, Ig_I-set, Laminin_G_1, Ig_V-set_subgr, LDrepeatLR_classA_rpt, EGF-like_Ca-bd
UniProt Accession P98160, B6EU51, Q5SZI5, Q5SZI6, Q5SZI9, Q5SZI8, Q5SZJ2, Q5SZJ1, Q5SZJ0
Gene-Disease Assocation SCHWARTZ-JAMPEL SYNDROME, TYPE 1; SJS1, DYSSEGMENTAL DYSPLASIA, SILVERMAN-HANDMAKER TYPE; DDSH
Search EB-eye ENSG00000142798
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-22541, E-GEOD-6573, E-GEOD-1577, ... (28 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (45 experiments)

Factor Value U/D Experiments
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
Daudi
2
E-MTAB-37, E-GEOD-96
GM15510
2
E-GEOD-19466, E-GEOD-22639
HCC1954
2
E-GEOD-29119, E-MTAB-37
KG1
2
E-MTAB-37, E-GEOD-24147
MOLT4
2
E-MTAB-37, E-MTAB-62
421 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-MEXP-66, E-GEOD-4219, ... (46 experiments)

Factor Value U/D Experiments
endothelial cell
3
E-GEOD-3920, E-GEOD-19240, E-GEOD-3998
CD8+ T cell
2
E-MTAB-25, E-AFMX-5
hematopoietic stem cell
2
E-MEXP-872, E-MEXP-1403
activated natural killer cell (supplemented for IL2 for 24 hours)
1
E-TABM-702
M1 macrophage
1
E-GEOD-5099
CD19+ B cell
1
1
E-MEXP-1600
90 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-1577, E-MEXP-1121, E-GEOD-16363, E-MTAB-62, ... (60 experiments)

Factor Value U/D Experiments
glioblastoma
5
E-GEOD-4290, E-GEOD-4412, E-MTAB-62, E-MTAB-37, E-GEOD-6014 ... (5 experiments)
dermatomyositis
2
E-GEOD-5370, E-GEOD-1551
lung carcinoma
2
E-MTAB-37, E-GEOD-6014
AIDS-KS, HIV+, nodular (late) stage
1
2
E-MTAB-62, E-MEXP-66
Duchenne muscular dystrophy
2
E-GEOD-3307, E-GEOD-1004
colon carcinoma
2
E-MTAB-62, E-MTAB-37
217 more value(s).


Compound treatment

studied in E-GEOD-6907, E-GEOD-5741, E-GEOD-15205, E-TABM-782, E-GEOD-3356, ... (22 experiments)

Factor Value U/D Experiments
glutamine
2
E-MEXP-1335, E-MEXP-941
none
3
4
E-GEOD-5824, E-MEXP-1958, E-GEOD-412, E-MEXP-1230, E-GEOD-5741, ... (7 experiments)
5-aza-2'-deoxycytidine + trichostatin A
2
1
E-MEXP-1269
unknown
1
E-GEOD-7307
mercaptopurine, methotrexate
1
E-GEOD-412
Cxcl12
1
1
E-GEOD-7307
31 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-21374, ... (7 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-1614, E-GEOD-20033, E-MTAB-62 ... (5 experiments)

Disease staging
studied in E-GEOD-19743, E-GEOD-22544, E-GEOD-3325, E-TABM-147, E-GEOD-19665, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-7011, E-GEOD-4025, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (9 experiments)

Genotype
studied in E-GEOD-3494, E-GEOD-21750, E-MEXP-421, E-GEOD-22593, E-GEOD-2292, ... (10 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-TABM-127, E-GEOD-20504, E-MEXP-1446, E-GEOD-9764, ... (8 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-16194, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-TABM-15, ... (29 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-17400

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-22056, E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-MEXP-958

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-21750, E-GEOD-1657

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, ... (7 experiments)

Replicate
studied in E-GEOD-18791

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-MEXP-548, E-GEOD-3697, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-19069, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-GEOD-19246, E-GEOD-19136, ... (8 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 00 005
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-4922

Processing time: 0.363 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM